Dalfampridine and Cardiac failure - a phase IV clinical study of FDA data

Summary:

Cardiac failure is reported as a side effect among people who take Dalfampridine (dalfampridine), especially for people who are female, 60+ old, have been taking the drug for 5 - 10 years also take Vitamin D3, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Cardiac failure when taking Dalfampridine. It is created by eHealthMe based on reports of 9,652 people who have side effects when taking Dalfampridine from the FDA, and is updated regularly.

What is Dalfampridine?

Dalfampridine has active ingredients of dalfampridine. eHealthMe is studying from 9,658 Dalfampridine users. Check the latest studies of Dalfampridine.

What is Cardiac failure?

Cardiac failure is found to be associated with 2,058 drugs and 2,210 conditions by eHealthMe. Check the latest studies of Cardiac failure.

On Jul, 07, 2026

9,652 people reported to have side effects when taking Dalfampridine.
Among them, 17 people (0.18%) have Cardiac failure.

Could Dalfampridine cause Cardiac failure?

Among these 17 people:

How long have people been on Dalfampridine when they have Cardiac failure? *

What is the gender of people who have Cardiac failure when taking Dalfampridine? *

female: 80 %
male: 20 %

What is the age of people who have Cardiac failure when taking Dalfampridine? *

What are other drugs people take besides Dalfampridine? *

What are other side effects people have besides Cardiac failure? *

General Physical Health Deterioration (weak health status): 7 people, 41.18%
Hypotension (abnormally low blood pressure): 5 people, 29.41%
Urinary Retention (the inability to completely or partially empty the bladder): 4 people, 23.53%
Dyspnea (difficult or laboured breathing): 4 people, 23.53%
Cough: 3 people, 17.65%
Cardiac Amyloidosis (protein deposition in heart): 3 people, 17.65%
Functional Gastrointestinal Disorder (functional problem in separate organs of gastrointestinal system): 3 people, 17.65%
Ejection Fraction Decreased (systolic heart failure): 3 people, 17.65%
Diarrhea: 3 people, 17.65%
Cross Sensitivity Reaction: 3 people, 17.65%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 12 people, 70.59%
Micturition Disorder (disease of passing urine): 3 people, 17.65%
Hypotension (abnormally low blood pressure): 3 people, 17.65%
Gait Disturbance: 3 people, 17.65%
Progressive Multiple Sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord): 2 people, 11.76%
Pain: 2 people, 11.76%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 5.88%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 5.88%
Neuralgia (pain in one or more nerves): 1 person, 5.88%
High Blood Pressure: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Dalfampridine and have Cardiac failure?

- Check whether Cardiac failure is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dalfampridine:

Dalfampridine (9,658 reports)

Cardiac failure treatments and more:

Cardiac failure (147,157 reports)

Browse all side effects of Dalfampridine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cardiac failure:

Cardiac failure (2,058 drugs)

Browse all the conditions that are associated with Cardiac failure:

Cardiac failure (2,210 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Dalfampridine) and Dalfampridine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.